再鼎医药(ZLAB)今日盘中大跌5.08%，引发了市场的广泛关注。
消息面上，公司此前公布的2026年第一季度财报显示，总收入为9960万美元，同比下滑6%，产品收入净额同比下降10%。具体来看，公司赖以起家的核心产品则乐（尼拉帕利）受集采后医院用药模式变化影响，收入出现显著下降；另一款产品卫伟迦也因医保续约降价而出现小幅下滑。此外，公司近期宣布由王轶喆博士负责商业化工作，商业化团队换帅的时点与业绩波动叠加，引发了市场对于公司治理是否稳定的疑虑。
尽管面临短期业绩压力，但分析指出，再鼎医药的全球创新管线，如zoci (ZL-1310)等，正在快速成熟并迎来关键催化剂，公司估值逻辑或正从“商业化收入驱动”向“研发管线价值驱动”切换。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.